Table 3.
Long-Term Clozapine Maintenance Rates for AOS and the NIH COS Population
| Study | Design | FU length (yrs) | n | Population description of subjects | Mean CLZ duration | Range of CLZ duration | Discontinued | Maintained |
|---|---|---|---|---|---|---|---|---|
| Adult-onset | ||||||||
| Juul Povlsen et al. (1985) | Retrospective open, chart | 12 | 216 | Primary diagnosis of SCH: 182 | 2.75 yrs | 0.08–12 yrs | 57.4% (124) | 42.6% (92) |
| Lindstrom (1988) | Retrospective | 13 | 96 | Chronic, treatment-resistant SCH: 89 Schizoaffective: 7 |
36.4% (35) | 57.3% (55)a | ||
| Mattes (1989) | Open study | 2 | 14 | Chronic, treatment-resistant | Two years after initiating study, 4.3 ± 3.6 mos | 57.1% (8) | 42.9% (6) | |
| Childhood-onset | ||||||||
| Rapoport et al. (2015) | Open study | 24 | 120 | Chronic, treatment-resistant | 6.9 ± 4.98 yrs | 1.024–23.5 yrs | 8.3% (10/120) | 72.5% (87/120) |
a
As calculated from manuscript data.
AOS, adult-onset schizophrenia; NIH, National Institutes of Health; COS, childhood-onset schizophrenia; FU, follow-up; SCH, schizophrenia.